A successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort

References

• Sánchez-Borges M, Martin BL, Muraro AM, et al. The importance of allergic disease in public health: an iCAALL statement. World Allergy Organ J. 2018;11(1):8. doi: 10.1186/s40413-018-0187-2
   PubMed Web of Science ®Google Scholar
• Klossek J, Annesi-Measano I, Boucot I, et al. Prevalence, severity and impact of allergic rhinitis in the French community survey instant 2006. Allergy. 2008;63(s88):158–611. doi: 10.1111/j.1398-9995.2008.01760.x
   Google Scholar
• Beasley R, The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The Lancet. 1998;351(9111):1225–1232. doi: 10.1016/S0140-6736(97)07302-9
   PubMed Web of Science ®Google Scholar
• Brożek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. doi: 10.1016/j.jaci.2017.03.050
   PubMed Web of Science ®Google Scholar
• Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, asthma & Immunology/European Academy of Allergy and clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–1296.e3. doi: 10.1016/j.jaci.2013.01.049
   PubMed Web of Science ®Google Scholar
• Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: allergic rhinitis - 2023. Int Forum Allergy Rhinol. 2023;13(4):293–859. doi: 10.1002/alr.23090
   PubMed Web of Science ®Google Scholar
• Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–798. doi: 10.1111/all.13317
   PubMed Web of Science ®Google Scholar
• Larsen JN, Broge L, Jacobi H. Allergy immunotherapy: the future of allergy treatment. Drug Discov Today. 2016;21(1):26–37. doi: 10.1016/j.drudis.2015.07.010
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Oppenheimer J, et al. Pharmacologic treatment of seasonal allergic rhinitis: synopsis of guidance from the 2017 joint task force on practice parameters. Ann Intern Med. 2017;167(12):876–881. doi: 10.7326/M17-2203
   PubMed Web of Science ®Google Scholar
• Agache I, Lau S, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019;74(5):855–873. doi: 10.1111/all.13749
   PubMed Web of Science ®Google Scholar
• Zielen S, Devillier P, Heinrich J, et al. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2018;73(1):165–177. doi: 10.1111/all.13213
   PubMed Web of Science ®Google Scholar
• Devillier P, Molimard M, Ansolabehere X, et al. Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: a retrospective database study in France. Allergy. 2019;74(7):1317–1326. doi: 10.1111/all.13705
   PubMed Web of Science ®Google Scholar
• Wahn U, Bachert C, Heinrich J, et al. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2019;74(3):594–604. doi: 10.1111/all.13598
   PubMed Web of Science ®Google Scholar
• Fritzsching B, Contoli M, Porsbjerg C, et al. Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study. Lancet Reg Health Eur. 2022;13:100275. doi: 10.1016/j.lanepe.2021.100275
   PubMedGoogle Scholar
• Bozek A, Foks A, Trzaska K, et al. Long-term effects of allergen sublingual immunotherapy. Adv Dermatol Allergol. 2020;37(6):943–947. doi: 10.5114/ada.2019.85365
   PubMed Web of Science ®Google Scholar
• Caimmi D, Demoly P. L’immunothérapie allergénique par APSI : place et perspectives pour le traitement et la prévention des allergies respiratoires ; le cas des pollinoses. Rev Fr Allergol. 2019;59(8):617–623. doi: 10.1016/j.reval.2019.07.007
   Google Scholar
• Haute Autorité de Santé. Études en vie réelle pour l’évaluation des médicaments et dispositifs médicaux. 2023. [cited 2023 Dec 15]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2021-06/guide_etude_en_vie_reelle_medicaments__dm.pdf
   Google Scholar
• Haute Autorité de Santé. Décision n° 2018.0028/DC/SEM du 21 février 2018 du collège de la Haute Autorité de santé portant adoption d’une recommandation sur les allergènes préparés spécialement pour un seul individu. 2022 [cited 2023 Dec 15]. Available from: https://www.has-sante.fr/jcms/c_2832239/fr/decision-n-2018-0028/dc/sem-du-21-fevrier-2018-du-college-de-la-haute-autorite-de-sante-portant-adoption-d-une-recommandation-sur-les-allergenes-prepares-specialement-pour-un-seul-individu-apsi
   Google Scholar
• Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–962. doi: 10.1002/pds.4233
   PubMed Web of Science ®Google Scholar
• Ballinger GA. Using Generalized Estimating Equations for Longitudinal Data Analysis. Organ Res Methods. 2004;7(2):127–150. doi: 10.1177/1094428104263672
   Web of Science ®Google Scholar
• Incorvaia C, Ridolo E, Bagnasco D, et al. Personalized medicine and allergen immunotherapy: the beginning of a new era? Clin Mol Allergy CMA. 2021;19(1):10. doi: 10.1186/s12948-021-00150-z
   PubMedGoogle Scholar
• Thétis-Soulié M, Hosotte M, Grozelier I, et al. The MaDo real-life study of dose adjustment of allergen immunotherapy liquid formulations in an indication of respiratory allergic disease: reasons, practices, and outcomes. Front Allergy. 2022;3:971155. doi: 10.3389/falgy.2022.971155
   PubMedGoogle Scholar
• Demoly P, Allaert FA, Lecasble M, et al. PRAGMA. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy. 2003;58(7):672–675. doi: 10.1034/j.1398-9995.2003.t01-1-00202.x
   PubMed Web of Science ®Google Scholar
• Devillier P, Demoly P, Molimard M. Allergen immunotherapy: what is the added value of real-world evidence from retrospective claims database studies? Expert Rev Respir Med. 2020;14(5):445–452. doi: 10.1080/17476348.2020.1733417
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Klimek L, Brüggenjürgen B, et al. Real-world evidence for the long-term effect of allergen immunotherapy: Current status on database-derived European studies. Allergy. 2022;77(12):3584–3592. doi: 10.1111/all.15506
   PubMed Web of Science ®Google Scholar
• Scailteux LM, Droitcourt C, Balusson F, et al. French administrative health care database (SNDS): the value of its enrichment. Therapie. 2019;74(2):215–223. doi: 10.1016/j.therap.2018.09.072
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Bagnasco D. Real-life studies in allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2021;21(4):361–367. doi: 10.1097/ACI.0000000000000757
   PubMed Web of Science ®Google Scholar
• Calderon MA, Demoly P. Integrating the evidence in allergen immunotherapy: why real-world data should be important for the practicing clinician? Allergy Asthma Proc. 2022;43(4):305–309. doi: 10.2500/aap.2022.43.220006
   PubMed Web of Science ®Google Scholar
• Paoletti G. Editorial: pharmacotherapy and evidence based medicine. Curr Opin Allergy Clin Immunol. 2022;22(4):257–258. doi: 10.1097/ACI.0000000000000831
   PubMed Web of Science ®Google Scholar
• Fritzsching B, Contoli M, Porsbjerg C, et al. Real-world evidence: methods for assessing long-term health and effectiveness of allergy immunotherapy. J Allergy Clin Immunol. 2022;149(3):881–883. doi: 10.1016/j.jaci.2021.12.781
   PubMed Web of Science ®Google Scholar
• Campbell JD, Perry R, Papadopoulos NG, et al. The REal life EVidence AssessmeNt tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. Clin Transl Allergy. 2019;9(1):21. doi: 10.1186/s13601-019-0256-9
   PubMedGoogle Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919
   PubMed Web of Science ®Google Scholar
• Allan V, Ramagopalan SV, Mardekian J, et al. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res. 2020;9(9):603–614. doi: 10.2217/cer-2020-0013
   PubMed Web of Science ®Google Scholar